Privacy Policy

 

What This Privacy Policy Covers

This policy covers how Prestium Pharma, Inc. (“we” or “us”) treats personal information that we collect and receive. Personal information is information about you that is personally identifiable like your name, address, email address, or phone number, and that is not otherwise publicly available. This policy does not apply to the practices of companies that we do not own or control, or to people that we do not employ or manage.

Information Collection and Use

We collect personal information about you when you transmit such information to us, and when you visit certain of our pages. We may combine information about you that we have with information we obtain from business partners or other companies. We may use information for the following general purposes: to customize the content you see, fulfill your requests for services, to respond to a job application or inquiry, improve our services, contact you, conduct research, and provide anonymous reporting for internal and external clients. In connection with a job application or inquiry, you may provide us with information about yourself, such as a resume or job application. We may use this information throughout our organization and its related entities for the purpose of employment consideration, and except when you instruct us otherwise, we will keep such information for future consideration. We automatically receive and record information on our server logs from your browser, including your IP Address and the page you request. We do not currently use cookies, but may determine to do so in the future.

Information Sharing and Disclosure

We do not rent, sell, or share personal information about you with other people except to provide services you’ve requested, when we have your permission, or under the following circumstances: we respond to subpoenas, court orders, or legal process, or to establish or exercise our legal rights or defend against legal claims; we believe it is necessary to share information in order to investigate, prevent, or take action regarding illegal activities; violations of our Terms and Conditions, or as otherwise required by law; and we transfer information about you if we are acquired by or merged with another company.

Confidentiality and Security

We limit access to personal information about you to employees whom we believe reasonably need to have that information to provide services to you or in order to perform their job functions. We are committed to protecting personal information from loss, misuse, disclosure, alteration, unauthorized access and destruction. We take all reasonable precautions to safeguard the confidentiality of personally identifiable information. We limit access to personal information about you to employees whom we believe reasonably need to have that information to provide services to you or in order to perform their job functions.

Changes to this Privacy Policy

We may modify this policy at our sole discretion at any time. We will notify you about significant changes in the way we treat personal information by placing a prominent notice on our site.

 Effective Date: 8.10.2012

 

 

 

 


IMPORTANT SAFETY INFORMATION


Full Prescribing Information


  • OLUX® (clobetasol propionate) Foam, 0.05% is for topical use only. Avoid contact with eyes.

  • OLUX Foam is a super-potent topical corticosteroid that has been shown to suppress the adrenals at 7.0 g of OLUX Foam per day. Lesser amounts of OLUX Foam were not studied.

  • Systemic absorption of topical corticosteroids has caused reversible adrenal suppression with the potential for glucocorticosteroid insufficiency after withdrawal of treatment. Evaluate patients periodically for evidence of HPA axis suppression.

  • Cushing's Syndrome, hyperglycemia, and glucosuria can also result from systemic absorption of topical corticosteroids. Use of OLUX Foam for longer than 2 weeks may suppress the immune system.

  • Pediatric patients may be more susceptible to systemic toxicity from equivalent doses due to their larger skin surface to body mass ratios. Use in children under 12 years of age is not recommended.

  • OLUX Foam should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

  • Caution should be exercised when OLUX Foam is administered to a nursing woman.

  • In clinical trials, the most common adverse events associated with the use of OLUX Foam were burning, dryness, and other reactions at the application site.

  • The propellant in this foam is flammable; patients should avoid fire, flame, and/or smoking during and immediately following application.








OLUX Foam is a corticosteroid indicated for treatment of moderate to severe plaque psoriasis of the scalp and mild to moderate plaque psoriasis of non-scalp regions of the body excluding the face and intertriginous areas in patients 12 years and older.